Come up with a name for your new list and we'll add to it:
AgeneBio raised a round of funding on November 18, 2013. Investors include
New Enterprise Associates.
AgeneBio is developing therapies for people who have Amnestic Mild Cognitive Impairment (aMCI) and Alzheimer's disease (AD). The company has a new clinical strategy to help address the therapeutic nee…